Tag
The AMETHYST Phase 2 trial demonstrated that litifilimab significantly improves skin symptoms in cutaneous lupus erythematosus with a favorable safety profile, marking a potential new targeted treatment for this challenging condition.
A comprehensive analysis reveals no significant sex differences in antipsychotic efficacy or dose-response in acute schizophrenia, though females show greater reduction in dropout rates and higher prolactin elevation.
A multicenter randomized trial comparing seven antipsychotics in acute schizophrenia shows olanzapine and risperidone outperform several agents in efficacy but differ markedly in side effects, clarifying treatment choices.
This article reviews the long-term safety and efficacy of satralizumab in neuromyelitis optica spectrum disorder based on the SAkuraMoon extension trial.
The IFM2017-03 phase 3 trial demonstrates that a dexamethasone-sparing regimen combining daratumumab with lenalidomide markedly improves progression-free survival in frail elderly multiple myeloma patients, without increasing serious advers
This phase I study demonstrates that DEP-SN38, a dendrimer-nanoparticle conjugate of SN38, is well tolerated with minimal gastrointestinal toxicity and shows encouraging antitumor activity in heavily pretreated advanced solid tumors.
Pre-stroke low-dose aspirin in distal medium vessel occlusion stroke patients undergoing mechanical thrombectomy is linked to improved 90-day functional outcomes and reduced mortality without increased symptomatic hemorrhage risk.
